187 related articles for article (PubMed ID: 21340657)
1. Trolamine emulsion for the prevention of radiation dermatitis in patients with squamous cell carcinoma of the head and neck.
Abbas H; Bensadoun RJ
Support Care Cancer; 2012 Jan; 20(1):185-90. PubMed ID: 21340657
[TBL] [Abstract][Full Text] [Related]
2. Phase III Trial of an emulsion containing trolamine for the prevention of radiation dermatitis in patients with advanced squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Trial 99-13.
Elliott EA; Wright JR; Swann RS; Nguyen-Tân F; Takita C; Bucci MK; Garden AS; Kim H; Hug EB; Ryu J; Greenberg M; Saxton JP; Ang K; Berk L;
J Clin Oncol; 2006 May; 24(13):2092-7. PubMed ID: 16648511
[TBL] [Abstract][Full Text] [Related]
3. Three-dimensional conformal radiotherapy (3D-CRT) versus intensity modulated radiation therapy (IMRT) in squamous cell carcinoma of the head and neck: a randomized controlled trial.
Gupta T; Agarwal J; Jain S; Phurailatpam R; Kannan S; Ghosh-Laskar S; Murthy V; Budrukkar A; Dinshaw K; Prabhash K; Chaturvedi P; D'Cruz A
Radiother Oncol; 2012 Sep; 104(3):343-8. PubMed ID: 22853852
[TBL] [Abstract][Full Text] [Related]
4. Randomized, self-controlled, prospective assessment of the efficacy of mometasone furoate local application in reducing acute radiation dermatitis in patients with head and neck squamous cell carcinomas.
Liao Y; Feng G; Dai T; Long F; Tang J; Pu Y; Zheng X; Cao S; Xu S; Du X
Medicine (Baltimore); 2019 Dec; 98(52):e18230. PubMed ID: 31876704
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic NS-21 maintains the skin moisture but does not reduce the severity of radiation dermatitis in patients with head and neck cancer: a randomized control trial.
Chou HL; Shueng PW; Liao LJ; Hsu CX; Kuo DY; Lo WC; Hou PY; Wang LY; Chou SF; Hsieh CH
Radiat Oncol; 2019 May; 14(1):90. PubMed ID: 31146741
[TBL] [Abstract][Full Text] [Related]
7. Prospective randomized controlled trial to compare 3-dimensional conformal radiotherapy to intensity-modulated radiotherapy in head and neck squamous cell carcinoma: Long-term results.
Ghosh-Laskar S; Yathiraj PH; Dutta D; Rangarajan V; Purandare N; Gupta T; Budrukkar A; Murthy V; Kannan S; Agarwal JP
Head Neck; 2016 Apr; 38 Suppl 1():E1481-7. PubMed ID: 26561342
[TBL] [Abstract][Full Text] [Related]
8. Locoregional Control and Toxicity in Head and Neck Carcinoma Patients following Helical Tomotherapy-Delivered Intensity-Modulated Radiation Therapy Compared with 3D-CRT Data.
Santa Cruz O; Tsoutsou P; Castella C; Khanfir K; Anchisi S; Bouayed S; Matzinger O; Ozsahin M
Oncology; 2018; 95(2):61-68. PubMed ID: 29895020
[TBL] [Abstract][Full Text] [Related]
9. Intensity-modulated radiation therapy versus three-dimensional conformal radiotherapy in head and neck squamous cell carcinoma: long-term and mature outcomes of a prospective randomized trial.
Gupta T; Sinha S; Ghosh-Laskar S; Budrukkar A; Mummudi N; Swain M; Phurailatpam R; Prabhash K; Agarwal JP
Radiat Oncol; 2020 Sep; 15(1):218. PubMed ID: 32938468
[TBL] [Abstract][Full Text] [Related]
10. Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program.
Vergeer MR; Doornaert PA; Rietveld DH; Leemans CR; Slotman BJ; Langendijk JA
Int J Radiat Oncol Biol Phys; 2009 May; 74(1):1-8. PubMed ID: 19111400
[TBL] [Abstract][Full Text] [Related]
11. Radical radiotherapy with concurrent weekly cisplatin in loco-regionally advanced squamous cell carcinoma of the head and neck: a single-institution experience.
Gupta T; Agarwal JP; Ghosh-Laskar S; Parikh PM; D'Cruz AK; Dinshaw KA
Head Neck Oncol; 2009 Jun; 1():17. PubMed ID: 19527507
[TBL] [Abstract][Full Text] [Related]
12. Reirradiation for patients with recurrence head and neck squamous cell carcinoma: a single-institution comparative study.
Rudžianskas V; Inčiūra A; Vaitkus S; Padervinskis E; Rudžianskienė M; Kupčinskaitė-Noreikienė R; Saltonaitė L; Noreika A; Statnickaitė A; Juozaitytė E
Medicina (Kaunas); 2014; 50(2):92-9. PubMed ID: 25172603
[TBL] [Abstract][Full Text] [Related]
13. Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The RTOG Experience.
Bar-Ad V; Zhang QE; Harari PM; Axelrod R; Rosenthal DI; Trotti A; Jones CU; Garden AS; Song G; Foote RL; Raben D; Shenouda G; Spencer SA; Harris J; Le QT
Int J Radiat Oncol Biol Phys; 2016 Aug; 95(5):1346-1354. PubMed ID: 27212198
[TBL] [Abstract][Full Text] [Related]
14. A monocentric, open-label randomized standard-of-care controlled study of XONRID®, a medical device for the prevention and treatment of radiation-induced dermatitis in breast and head and neck cancer patients.
Ingargiola R; De Santis MC; Iacovelli NA; Facchinetti N; Cavallo A; Ivaldi E; Dispinzieri M; Franceschini M; Giandini C; Romanello DA; Di Biaso S; Sabetti M; Locati L; Alfieri S; Bossi P; Guglielmo M; Macchi F; Lozza L; Valdagni R; Fallai C; Pignoli E; Orlandi E
Radiat Oncol; 2020 Aug; 15(1):193. PubMed ID: 32791985
[TBL] [Abstract][Full Text] [Related]
15. [SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity].
Kiprian D; Jarząbski A; Pawłowska B; Michalski W; Kawecki A
Otolaryngol Pol; 2011 Sep; 65(5 Suppl):117-25. PubMed ID: 22000261
[TBL] [Abstract][Full Text] [Related]
16. Phase III randomized trial of Calendula officinalis compared with trolamine for the prevention of acute dermatitis during irradiation for breast cancer.
Pommier P; Gomez F; Sunyach MP; D'Hombres A; Carrie C; Montbarbon X
J Clin Oncol; 2004 Apr; 22(8):1447-53. PubMed ID: 15084618
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer.
Ferris RL; Geiger JL; Trivedi S; Schmitt NC; Heron DE; Johnson JT; Kim S; Duvvuri U; Clump DA; Bauman JE; Ohr JP; Gooding WE; Argiris A
Ann Oncol; 2016 Dec; 27(12):2257-2262. PubMed ID: 27733374
[TBL] [Abstract][Full Text] [Related]
18. Effect of HMB/Arg/Gln on the prevention of radiation dermatitis in head and neck cancer patients treated with concurrent chemoradiotherapy.
Imai T; Matsuura K; Asada Y; Sagai S; Katagiri K; Ishida E; Saito D; Sadayasu R; Wada H; Saijo S
Jpn J Clin Oncol; 2014 May; 44(5):422-7. PubMed ID: 24688085
[TBL] [Abstract][Full Text] [Related]
19. High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes.
Giro C; Berger B; Bölke E; Ciernik IF; Duprez F; Locati L; Maillard S; Ozsahin M; Pfeffer R; Robertson AG; Langendijk JA; Budach W
Radiother Oncol; 2009 Feb; 90(2):166-71. PubMed ID: 18977050
[TBL] [Abstract][Full Text] [Related]
20. Smart (simultaneous modulated accelerated radiation therapy) boost: a new accelerated fractionation schedule for the treatment of head and neck cancer with intensity modulated radiotherapy.
Butler EB; Teh BS; Grant WH; Uhl BM; Kuppersmith RB; Chiu JK; Donovan DT; Woo SY
Int J Radiat Oncol Biol Phys; 1999 Aug; 45(1):21-32. PubMed ID: 10477002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
